Pregled bibliografske jedinice broj: 1017292
Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes
Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes // FEBS letters, 593 (2019), 13; 1598-1615 doi:10.1002/1873-3468.13495 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 1017292 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Altered N-glycosylation profiles as potential biomarkers and drug targets in diabetes
Autori
Rudman, Najda ; Gornik, Olga ; Lauc, Gordan
Izvornik
FEBS letters (0014-5793) 593
(2019), 13;
1598-1615
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
glycosyltransferase ; HNF1A-MODY ; N-glycosylation ; type 1 diabetes ; type 2 diabetes
Sažetak
N-glycosylation is a ubiquitous protein modification, and N-glycosylation profiles are emerging as both biomarkers and functional effectors in various types of diabetes. Genome- wide association studies identified glycosyltransferase genes as candidate causal genes for type 1 and type 2 diabetes. Studies focused on N-glycosylation changes in type 2 diabetes demonstrated that patients can be distinguished from healthy controls based on N- glycome composition. In addition, individuals at an increased risk of future disease development could be identified based on N- glycome profiles. Moreover, accumulating evidence indicates that N-glycans have a major role in preventing the impairment of glucose- stimulated insulin secretion by maintaining the glucose transporter in proper orientation, indicating that interindividual variation in protein N-glycosylation might be a novel risk factor contributing to diabetes development. Defective N-glycosylation of T cells has been implicated in type 1 diabetes pathogenesis. Furthermore, studies of N-glycan alterations have successfully been used to identify individuals with rare types of diabetes (such as the HNF1A-MODY), and also to evaluate functional significance of novel diabetes- associated mutations. In conclusion, both N- glycans and glycosyltransferases emerge as potential therapeutic targets in diabetes.
Izvorni jezik
Engleski
Znanstvena područja
Interdisciplinarne prirodne znanosti
POVEZANOST RADA
Projekti:
721815 - Innovative training in methods for future data (IMforFUTURE) (Zoldoš, Vlatka; Lauc, Gordan, EK - H2020-MSCA-ITN-2016) ( CroRIS)
KK.01.2.1.01.0003
KK.01.1.1.01.0010
HRZZ-UIP-2014-09-7769 - Glikozilacija plazmatskih proteina u razumijevanju dijabetesa tipa 1 (GLYCO-T1D) (Gornik, Olga, HRZZ - 2014-09) ( CroRIS)
722095 - Exploitation of Glycosylation Signatures for Precision Medicine (GlySign) (EK - H2020-MSCA-ITN-2016) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
GENOS d.o.o.
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE